UBS predicts high sales potential for Tyvaso, a drug whose market success is linked to NIH data and the broader treatment landscape.
2 reports, 2 independent
Updated Sep 3
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
UBS predicts high sales potential for Tyvaso, a drug whose market success is linked to NIH data and the broader treatment landscape.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- United Therapeutics announced an expanded partnership with MannKind, covering a new development product.Sub-event
UBS predicts high sales potential for Tyvaso, backed by NIH data.1 source
Martine Rothblatt is the CEO of United Therapeutics.1 source
Keep exploring
The entities involved
-
UBS
Swiss multinational investment bank and financial services company
-
United Therapeutics
biotech company based in Silver Spring, Maryland, United States
-
National Institutes of Health
government organization in Shah Alam, Malaysia
Coverage
Newest first; wire copies grouped- The Daily UpsideLung Disease Breakthrough Boosts United Therapeutics — and its Rivals United Therapeutics shares rose a breathtaking 33% on Tuesday — actually, it might be more appropriate to say they rose a breath-
- Business WireUnited Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis Positive results were observed across all subgroup